Pharmaceutical

NVP-1805R2 by NVP Healthcare for Unspecified Cardiovascular Disorders: Likelihood of Approval

NVP-1805R2 is under clinical development by NVP Healthcare and currently in Phase I for Unspecified Cardiovascular Disorders.

Dec 31, 2024 - 06:00
NVP-1805R2 is under clinical development by NVP Healthcare and currently in Phase I for Unspecified Cardiovascular Disorders.
Read the original article

Tags:

Previous Article

Xaluritamig by Amgen for Prostate Cancer: Likelihood of Approval

Next Article

Tevimbra by BeiGene for Muscle Invasive Bladder Cancer (MIBC): Likelihood of App...

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Vanda acquires rights to Actelion’s multiple sclerosis drug

Vanda acquires rights to Actelion’s multiple sclerosis ...

Dec 8, 2023

STAT+: At JPM, Bristol’s new CEO appeals to history to try to soothe investors’ nerves

STAT+: At JPM, Bristol’s new CEO appeals to history to ...

Jan 8, 2024

STAT+: Pharmalittle: Curevac loses key patent in battle with BioNTech; Abernethy to step down as Verily CMO

STAT+: Pharmalittle: Curevac loses key patent in battle...

Dec 21, 2023